Impact of MMX- mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 386-396

  Hodgkins, Paul ^a   Yen, Linnette ^a   Yarlas, Aaron ^b   Karlstadt, Robyn ^a   Solomon, Dory ^a   Kane, Sunanda ^c  

^a SHIRE   (United States)

^b QualityMetric Incorporated   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Health related quality of life; MMX mesalamine; SF 12; Ulcerative colitis

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM HEMORRHAGE; SCORING SYSTEM; TREATMENT DURATION; ULCERATIVE COLITIS; UNITED STATES; AGED; COST OF ILLNESS; DRUG ADMINISTRATION; FOLLOW UP; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COST OF ILLNESS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84876414188     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.23022     Document Type: Article

References (41)

1. Janke KH, Raible A, Bauer M, et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis. 2004;19: 343-353.
2. Bernklev T, Jahnsen J, Lygren I, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form- 36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11:909-918.
3. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272- 286.
4. Nordin K, Pahlman L, Larsson K, et al. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:450- 457.
5. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:1135-1140.
6. Adler J, Raju S, Beveridge AS, et al. College adjustment in University of Michigan students with Crohn's and colitis. Inflamm Bowel Dis. 2008;14: 1281-1286.
7. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004;39:365-373.
8. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488-496.
9. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
10. Larsson K, Loof L, Ronnblom A, et al. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res. 2008;64:139-148.
11. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14: 1575-1584.
12. McColl E, Han SW, Barton JR, et al. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res. 2004;13:805- 811.
13. Mokrowiecka A, Jurek K, Pinkowski D, et al. The comparison of healthrelated quality of life (HRQL) in patients with GERD, pepticulcer disease and ulcerative colitis. Adv Med Sci. 2006;51:142-147.
14. Pallis AG, Vlachonikolis IG, Mouzas IA. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol. 2002;2:1.
15. Zahn A, Hinz U, Karner M, et al. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demo graphic features in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12: 1058-1067.
16. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14:554-565.
17. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007;102:794-802.
18. Irvine EJ, Yeh CH, Ramsey D, et al. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1278-1286.
19. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-16.
20. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.
21. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
22. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75.
23. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twicedaily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
24. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005; 11:421-427.
25. Connolly MP, Poole CD, Currie CJ, et al. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion. 2009; 80:241-246.
26. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672-678.
27. Robinson M, Hanauer S, Hoop R, et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994;8:27-34.
28. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893-902.
29. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8.
30. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008;27:1094-1102.
31. Ware JE, Kosinski M, Turner-Bowker DM, et al. User's Manual for the SF-12v2 Health Survey. Lincoln, RI: QualityMetric; 2002.
32. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of mmx mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18:1026-1033.
33. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
34. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
35. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
36. Ware JE Jr, Kosinski M, Bjorner JB, et al. User's Manual for the SF-36v2 Health Survey. Lincoln, RI: QualityMetric; 2007.
37. Fayers PM, King MT. How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses. Qual Life Res. 2009; 18:527-530.
38. Kane S, Solomon D, Palmen M, et al. Long-term use of MMX-mesalazine 2.4 g/day is well tolerated in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2010;25:A91.
39. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX multi matrix system mesalazine for the induction of remission in patients with mild-tomoderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharma col Ther. 2007; 26:205-215.
40. Duan B, Dunlap WP. The accuracy of different methods for estimating the standard error of correlations corrected for range restriction. Educ Psychol Measure. 1997;57:254-265.
41. Mendoza JL, Hart DE, Powell A. A bootstrap confidence interval based on a correlation corrected for range restriction. Multivariate Behav Res. 1991;26:255-269.